WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will present new Phase 3 analyses showing its FDA-approved YCANTH treatment produced higher molluscum contagiosum clearance rates than vehicle regardless of disease duration, alongside Phase 2 findings from its experimental basal cell carcinoma therapy at two dermatology conferences this month.
A post-hoc pooled analysis of two completed Phase 3 YCANTH trials found 48.9% of treated patients who had molluscum for 12 months or less achieved complete lesion clearance by Day 84, compared with 16.7% receiving vehicle.
Among patients with disease lasting more than 12 months, complete clearance reached 58.8% with YCANTH versus 5% with vehicle. Both comparisons had p-values below 0.0001.
Median lesion-count reduction was 100% with YCANTH in both disease-duration groups, compared with 47.9% for vehicle among patients with disease lasting 12 months or less and 50.9% among those with longer disease duration.
Verrica said the median YCANTH-treated patient experienced at least 2.3 times greater lesion-count reduction than the typical vehicle-treated patient at Day 84 regardless of time since diagnosis.
“The disease duration findings for YCANTH are based on a new post-hoc analysis,” Chief Executive Officer Jayson Rieger said, adding that the results demonstrate treatment benefit “regardless of whether patients have recently contracted molluscum or have suffered for greater than 12 months with their lesions.”
YCANTH, also known as VP-102, is a drug-device combination containing cantharidin administered through a single-use applicator. It is FDA-approved for healthcare professional-administered treatment of molluscum contagiosum in adults and children age 2 and older.
The treatment is also approved for molluscum contagiosum in Japan following an additional Phase 3 study of about 300 patients. Verrica is studying YCANTH in a global Phase 3 program in the U.S. and Japan for common warts.
Verrica will separately present an exploratory analysis of VP-315, or ruxotemitide, from Part 2 of a multicenter Phase 2 basal cell carcinoma study. The analysis previously appeared at the 2026 Society for Investigative Dermatology Annual Meeting.
Investigators observed a mean reduction in tumor size across 14 untreated non-target lesions after separate target lesions received intratumoral VP-315. Three of the 14 untreated lesions achieved complete histological clearance, according to the company.
Chief Medical Officer Noah Rosenberg said the observed “abscopal-like activity” in untreated lesions suggests a potential immune effect extending beyond tumors directly treated with VP-315.
VP-315 is an investigational oncolytic peptide immunotherapy administered directly into tumors. Verrica holds an exclusive worldwide license to develop and commercialize the therapy for certain dermatologic oncology indications and intends to initially focus development on basal cell and squamous cell carcinomas.
Both posters will be presented at Maui Derm NP+PA Fall 2026, running Sept. 16-19 at The Greenbrier in White Sulphur Springs, West Virginia, and the 27th Annual Las Vegas Dermatology Seminar, scheduled for Sept. 17-20 at the Bellagio in Las Vegas.
Additional information about YCANTH is available at YCANTHPro.com.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.